Difference between revisions of "Surgery for pleural mesothelioma"
(Added to operating room setup) |
(Added citations; completed section on preoperative management) |
||
Line 1: | Line 1: | ||
Malignant pleural mesothelioma (MPM) is an aggressive disease, is often diagnosed at an advanced stage, and has a 5-year survival rate of only 5 to 10%. The most important risk factor for its development is exposure to asbestos; the transformation of work practices worldwide has led to a modest decline in incidence. The three primary histologic types are epithelioid, sarcomatoid, and biphasic or mixed histology, with epithelioid resulting in more favorable outcomes than sarcomatoid or mixed histology. | Malignant pleural mesothelioma (MPM) is an aggressive disease, is often diagnosed at an advanced stage, and has a 5-year survival rate of only 5 to 10%.<ref>{{Cite journal|last=Janes|first=Sam M.|last2=Alrifai|first2=Doraid|last3=Fennell|first3=Dean A.|date=2021-09-23|editor-last=Longo|editor-first=Dan L.|title=Perspectives on the Treatment of Malignant Pleural Mesothelioma|url=http://www.nejm.org/doi/10.1056/NEJMra1912719|journal=New England Journal of Medicine|language=en|volume=385|issue=13|pages=1207–1218|doi=10.1056/NEJMra1912719|issn=0028-4793}}</ref> The most important risk factor for its development is exposure to asbestos; the transformation of work practices worldwide has led to a modest decline in incidence. The three primary histologic types are epithelioid, sarcomatoid, and biphasic or mixed histology, with epithelioid resulting in more favorable outcomes than sarcomatoid or mixed histology.<ref>{{Cite journal|last=Neragi-Miandoab|first=Siyamek|last2=Richards|first2=William G.|last3=Sugarbaker|first3=David J.|date=2008-08-01|title=Morbidity, mortality, mean survival, and the impact of histology on survival after pleurectomy in 64 patients with malignant pleural mesothelioma|url=https://www.sciencedirect.com/science/article/pii/S1743919108000605|journal=International Journal of Surgery|language=en|volume=6|issue=4|pages=293–297|doi=10.1016/j.ijsu.2008.04.004|issn=1743-9191}}</ref><ref>{{Cite journal|last=Vigneswaran|first=Wickii T.|last2=Kircheva|first2=Diana Y.|last3=Ananthanarayanan|first3=Vijayalakshimi|last4=Watson|first4=Sydeaka|last5=Arif|first5=Qudsia|last6=Celauro|first6=Amy Durkin|last7=Kindler|first7=Hedy L.|last8=Husain|first8=Aliya N.|date=2017-03|title=Amount of Epithelioid Differentiation Is a Predictor of Survival in Malignant Pleural Mesothelioma|url=https://linkinghub.elsevier.com/retrieve/pii/S0003497516311316|journal=The Annals of Thoracic Surgery|language=en|volume=103|issue=3|pages=962–966|doi=10.1016/j.athoracsur.2016.08.063}}</ref> | ||
One of two operations is performed: extrapleural pneumonectomy (EPP) and pleurectomy/decortication (P/D). EPP is the radical en bloc resection of the lung, pleura, diaphragm, and pericardium. P/D is a lung-sparing but still radical procedure in which the diseased pleural envelope that encases and constricts the lung is dissected from the chest wall, mediastinum, diaphram, and pericardium, and then is stripped from the surface of the lung. P/D is the more frequently used approach as of this writing as EPP has shown no survival advantage and patients experience improved quality of life when the lung remains intact. | One of two operations is performed: extrapleural pneumonectomy (EPP) and pleurectomy/decortication (P/D). EPP is the radical en bloc resection of the lung, pleura, diaphragm, and pericardium. P/D is a lung-sparing but still radical procedure in which the diseased pleural envelope that encases and constricts the lung is dissected from the chest wall, mediastinum, diaphram, and pericardium, and then is stripped from the surface of the lung.<ref>{{Cite journal|last=Wolf|first=Andrea S.|last2=Daniel|first2=Jonathan|last3=Sugarbaker|first3=David J.|date=2009-06-01|title=Surgical Techniques for Multimodality Treatment of Malignant Pleural Mesothelioma: Extrapleural Pneumonectomy and Pleurectomy/Decortication|url=https://www.semthorcardiovascsurg.com/article/S1043-0679(09)00084-7/abstract|journal=Seminars in Thoracic and Cardiovascular Surgery|language=English|volume=21|issue=2|pages=132–148|doi=10.1053/j.semtcvs.2009.07.007|issn=1043-0679|pmid=19822285}}</ref><ref>{{Cite journal|last=Ng|first=Ju-Mei|last2=Hartigan|first2=Philip M.|date=2008-02|title=Anesthetic management of patients undergoing extrapleural pneumonectomy for mesothelioma|url=https://journals.lww.com/co-anesthesiology/Abstract/2008/02000/Anesthetic_management_of_patients_undergoing.6.aspx|journal=Current Opinion in Anesthesiology|language=en-US|volume=21|issue=1|pages=21–27|doi=10.1097/ACO.0b013e3282f2a9c3|issn=0952-7907}}</ref><ref>{{Cite journal|last=Vlahu|first=Tedi|last2=Vigneswaran|first2=Wicki T.|date=2017-07|title=Pleurectomy and decortication|url=http://atm.amegroups.com/article/view/14825/15364|journal=Annals of Translational Medicine|volume=5|issue=11|pages=246–246|doi=10.21037/atm.2017.04.03|pmc=PMC5497109|pmid=28706914}}</ref>P/D is the more frequently used approach as of this writing as EPP has shown no survival advantage and patients experience improved quality of life when the lung remains intact.<ref>{{Cite journal|last=Infante|first=Maurizio|last2=Morenghi|first2=Emanuela|last3=Bottoni|first3=Edoardo|last4=Zucali|first4=Paolo|last5=Rahal|first5=Daoud|last6=Morlacchi|first6=Andrea|last7=Ascolese|first7=Anna Maria|last8=De Rose|first8=Fiorenza|last9=Navarria|first9=Pierina|last10=Crepaldi|first10=Alessandro|last11=Testori|first11=Alberto|date=2016-12|title=Comorbidity, postoperative morbidity and survival in patients undergoing radical surgery for malignant pleural mesothelioma|url=https://academic.oup.com/ejcts/article-lookup/doi/10.1093/ejcts/ezw215|journal=European Journal of Cardio-Thoracic Surgery|language=en|volume=50|issue=6|pages=1077–1082|doi=10.1093/ejcts/ezw215|issn=1010-7940}}</ref><ref>{{Cite journal|last=Sugarbaker|first=David J|last2=Wolf|first2=Andrea S|date=2010-06|title=Surgery for malignant pleural mesothelioma|url=http://www.tandfonline.com/doi/full/10.1586/ers.10.35|journal=Expert Review of Respiratory Medicine|language=en|volume=4|issue=3|pages=363–372|doi=10.1586/ers.10.35|issn=1747-6348}}</ref><ref>{{Cite journal|last=Neragi-Miandoab|first=S.|last2=Weiner|first2=S.|last3=Sugarbaker|first3=D. J.|date=2008-12-01|title=Incidence of atrial fibrillation after extrapleural pneumonectomy vs. pleurectomy in patients with malignant pleural mesothelioma|url=https://academic.oup.com/icvts/article-lookup/doi/10.1510/icvts.2008.181099|journal=Interactive CardioVascular and Thoracic Surgery|language=en|volume=7|issue=6|pages=1039–1042|doi=10.1510/icvts.2008.181099|issn=1569-9293}}</ref> | ||
Currently a multi-center trial, MARS 2, is ongoing in the UK to test the hypothesis that P/D and chemotherapy is superior to chemotherapy alone with respect to overall survival for patients with pleural mesothelioma. The trial will also examine a range of secondary outcomes including adverse health events and cost-effectiveness. If the results of this trial are negative, there will be reason to question if radical surgery, as opposed to palliative procedures such as PleurX catheter insertion, should continue to have a role in the treatment of mesothelioma. | Currently a multi-center trial, MARS 2, is ongoing in the UK to test the hypothesis that P/D and chemotherapy is superior to chemotherapy alone with respect to overall survival for patients with pleural mesothelioma. The trial will also examine a range of secondary outcomes including adverse health events and cost-effectiveness. If the results of this trial are negative, there will be reason to question if radical surgery, as opposed to palliative procedures such as PleurX catheter insertion, should continue to have a role in the treatment of mesothelioma.<ref>{{Cite journal|last=Lim|first=Eric|last2=Darlison|first2=Liz|last3=Edwards|first3=John|last4=Elliott|first4=Daisy|last5=Fennell|first5=D A|last6=Popat|first6=Sanjay|last7=Rintoul|first7=Robert C|last8=Waller|first8=David|last9=Ali|first9=Clinton|last10=Bille|first10=Andrea|last11=Fuller|first11=Liz|date=2020-08|title=Mesothelioma and Radical Surgery 2 (MARS 2): protocol for a multicentre randomised trial comparing (extended) pleurectomy decortication versus no (extended) pleurectomy decortication for patients with malignant pleural mesothelioma|url=https://bmjopen.bmj.com/lookup/doi/10.1136/bmjopen-2020-038892|journal=BMJ Open|language=en|volume=10|issue=9|pages=e038892|doi=10.1136/bmjopen-2020-038892|issn=2044-6055|pmc=PMC7467531|pmid=32873681}}</ref> | ||
This article will focus on the anesthetic management of radical pleurectomy/decortication, which is done via open thoracotomy with one-lung ventilation by double-lumen endotracheal tube. These procedures may last for eight hours or more, and typically involve substantial blood and fluid loss. Most centers send patients directly to ICU whether or not extubation is possible at the conclusion of surgery. | This article will focus on the anesthetic management of radical pleurectomy/decortication, which is done via open thoracotomy with one-lung ventilation by double-lumen endotracheal tube. These procedures may last for eight hours or more, and typically involve substantial blood and fluid loss. Most centers send patients directly to ICU whether or not extubation is possible at the conclusion of surgery. | ||
== Preoperative management == | == Preoperative management == | ||
Patients may present for P/D with substantial disease burden including decreased lung function on the affected side, pleural or pericardial effusion, anemia, poor nutritional status, and effects of neoadjuvant chemotherapy. If possible, prehabilitation in preparation for surgery should be considered to correct anemia, improve nutritional status, and improve functional capacity. | Patients may present for P/D with substantial disease burden including decreased lung function on the affected side, pleural or pericardial effusion, anemia, poor nutritional status, and effects of neoadjuvant chemotherapy. If possible, prehabilitation in preparation for surgery should be considered to correct anemia, improve nutritional status, and improve functional capacity. | ||
* Patient evaluation | * Patient evaluation | ||
Line 33: | Line 33: | ||
|} | |} | ||
=== Operating room setup === | === Operating room setup === | ||
The operating room setup will be for open thoracotomy with an operating room table that can | The operating room setup will be for open thoracotomy with an operating room table that can be flexed.p- A checklist for equipment and supplies typically will include: | ||
# Double-lumen endotracheal tube | # Double-lumen endotracheal tube | ||
# Fiberoptic bronchoscope | # Fiberoptic bronchoscope | ||
# Video laryngoscope | # Video laryngoscope | ||
# Arterial | # Arterial line setup and transducer | ||
# Consider flow parameter monitoring (e.g. FloTrac system, Edwards Lifesciences) | # Consider flow parameter monitoring (e.g. FloTrac system, Edwards Lifesciences) | ||
# IV fluid warming device | # IV fluid warming device | ||
# Infusion pumps for vasoactive infusion | # Infusion pumps for vasoactive infusion | ||
# Availability of cross-matched blood, albumin | # Availability of cross-matched blood, albumin | ||
# CPAP equipment with airflow and PEEP control | |||
=== Patient preparation and premedication | === Patient preparation and premedication === | ||
=== Regional and neuraxial techniques | Patients should fast per institutional guidelines. Premedication is at the choice of the anesthesiologist depending on the patient's age and other relevant factors. | ||
=== Regional and neuraxial techniques === | |||
Thoracic epidural analgesia is highly recommended as it will benefit the patient's ability to breathe comfortably and resume mobility after the extensive thoracotomy required for radical mesothelioma resection. | |||
The epidural catheter should be inserted at a high enough level that the patient will not have any lumbar motor block and can safely ambulate. Insertion prior to surgery offers the advantage of beginning epidural infusion before the patient emerges from anesthesia. | |||
As there will be continuous blood and fluid loss throughout surgery, it may be preferred not to give any bolus dose or epidural infusion until close to the end of surgery to avoid the effects of sympathectomy. This decision must be weighed against the potential analgesic value of preemptive dosing. | |||
If the patient has a contraindication to epidural catheter placement, other regional techniques may be considered: lumbar spinal opioid analgesia, erector spinae plane block <ref>{{Cite journal|last=Adhikary|first=SanjibDas|last2=Pruett|first2=Ashlee|last3=Forero|first3=Mauricio|last4=Thiruvenkatarajan|first4=Venkatesan|date=2018|title=Erector spinae plane block as an alternative to epidural analgesia for post-operative analgesia following video-assisted thoracoscopic surgery: A case study and a literature review on the spread of local anaesthetic in the erector spinae plane|url=http://www.ijaweb.org/text.asp?2018/62/1/75/223077|journal=Indian Journal of Anaesthesia|language=en|volume=62|issue=1|pages=75|doi=10.4103/ija.IJA_693_17|issn=0019-5049|pmc=PMC5787896|pmid=29416155}}</ref>, intercostal or paravertebral blocks. | |||
== Intraoperative management == | == Intraoperative management == | ||
Line 104: | Line 114: | ||
== References == | == References == | ||
# Janes S, Alrefai D, Fennell D. Perspectives on the Treatment of Malignant Pleural Mesothelioma. N Engl J Med 2021; 385:1207-18. [[DOI: 10.1056/NEJMra1912719]] | # Janes S, Alrefai D, Fennell D. Perspectives on the Treatment of Malignant Pleural Mesothelioma. N Engl J Med 2021; 385:1207-18. [[DOI: 10.1056/NEJMra1912719|DOI: 10.1056/NEJMra1912719.]] | ||
# Neragi-Miandoab, Siyamek, William G. Richards, and David J. Sugarbaker. “Morbidity, Mortality, Mean Survival, and the Impact of Histology on Survival after Pleurectomy in 64 Patients with Malignant Pleural Mesothelioma.” International Journal of Surgery (London, England) 6, no. 4 (August 2008): 293–97. https://doi.org/10.1016/j.ijsu.2008.04.004. | |||
# Vigneswaran, Wickii T., Diana Y. Kircheva, Vijayalakshimi Ananthanarayanan, Sydeaka Watson, Qudsia Arif, Amy Durkin Celauro, Hedy L. Kindler, and Aliya N. Husain. “Amount of Epithelioid Differentiation Is a Predictor of Survival in Malignant Pleural Mesothelioma.” The Annals of Thoracic Surgery 103, no. 3 (March 1, 2017): 962–66. https://doi.org/10.1016/j.athoracsur.2016.08.063. | |||
# Wolf, Andrea S., Jonathan Daniel, and David J. Sugarbaker. “Surgical Techniques for Multimodality Treatment of Malignant Pleural Mesothelioma: Extrapleural Pneumonectomy and Pleurectomy/Decortication.” Seminars in Thoracic and Cardiovascular Surgery, Multimodality Management of Malignant Pleural Mesothelioma, 21, no. 2 (June 1, 2009): 132–48. https://doi.org/10.1053/j.semtcvs.2009.07.007. | # Wolf, Andrea S., Jonathan Daniel, and David J. Sugarbaker. “Surgical Techniques for Multimodality Treatment of Malignant Pleural Mesothelioma: Extrapleural Pneumonectomy and Pleurectomy/Decortication.” Seminars in Thoracic and Cardiovascular Surgery, Multimodality Management of Malignant Pleural Mesothelioma, 21, no. 2 (June 1, 2009): 132–48. https://doi.org/10.1053/j.semtcvs.2009.07.007. | ||
# Ng, Ju-Mei, and Philip M. Hartigan. “Anesthetic Management of Patients Undergoing Extrapleural Pneumonectomy for Mesothelioma.” Current Opinion in Anesthesiology 21, no. 1 (February 2008): 21. https://doi.org/10.1097/ACO.0b013e3282f2a9c3. | # Ng, Ju-Mei, and Philip M. Hartigan. “Anesthetic Management of Patients Undergoing Extrapleural Pneumonectomy for Mesothelioma.” Current Opinion in Anesthesiology 21, no. 1 (February 2008): 21. https://doi.org/10.1097/ACO.0b013e3282f2a9c3. | ||
# Vlahu, Tedi, and Wicki T. Vigneswaran. “Pleurectomy and Decortication.” Annals of Translational Medicine 5, no. 11 (June 2017). https://doi.org/10.21037/atm.2017.04.03. | # Vlahu, Tedi, and Wicki T. Vigneswaran. “Pleurectomy and Decortication.” Annals of Translational Medicine 5, no. 11 (June 2017). https://doi.org/10.21037/atm.2017.04.03. | ||
# Infante, Maurizio, Emanuela Morenghi, Edoardo Bottoni, Paolo Zucali, Daoud Rahal, Andrea Morlacchi, Anna Maria Ascolese, et al. “Comorbidity, Postoperative Morbidity and Survival in Patients Undergoing Radical Surgery for Malignant Pleural Mesothelioma.” European Journal of Cardio-Thoracic Surgery 50, no. 6 (December 2016): 1077–82. https://doi.org/10.1093/ejcts/ezw215. | # Infante, Maurizio, Emanuela Morenghi, Edoardo Bottoni, Paolo Zucali, Daoud Rahal, Andrea Morlacchi, Anna Maria Ascolese, et al. “Comorbidity, Postoperative Morbidity and Survival in Patients Undergoing Radical Surgery for Malignant Pleural Mesothelioma.” European Journal of Cardio-Thoracic Surgery 50, no. 6 (December 2016): 1077–82. https://doi.org/10.1093/ejcts/ezw215. | ||
# Sugarbaker, David J, and Andrea S Wolf. “Surgery for Malignant Pleural Mesothelioma.” Expert Review of Respiratory Medicine 4, no. 3 (June 2010): 363–72. https://doi.org/10.1586/ers.10.35. | # Sugarbaker, David J, and Andrea S Wolf. “Surgery for Malignant Pleural Mesothelioma.” Expert Review of Respiratory Medicine 4, no. 3 (June 2010): 363–72. https://doi.org/10.1586/ers.10.35. | ||
# Neragi-Miandoab, Siyamek, Shoshana Weiner, and David J. Sugarbaker. “Incidence of Atrial Fibrillation after Extrapleural Pneumonectomy vs. Pleurectomy in Patients with Malignant Pleural Mesothelioma.” Interactive Cardiovascular and Thoracic Surgery 7, no. 6 (December 2008): 1039–42. https://doi.org/10.1510/icvts.2008.181099. | # Neragi-Miandoab, Siyamek, Shoshana Weiner, and David J. Sugarbaker. “Incidence of Atrial Fibrillation after Extrapleural Pneumonectomy vs. Pleurectomy in Patients with Malignant Pleural Mesothelioma.” Interactive Cardiovascular and Thoracic Surgery 7, no. 6 (December 2008): 1039–42. https://doi.org/10.1510/icvts.2008.181099. | ||
# | # Lim E, Darlison L, Edwards J On behalf of MARS 2 Trialists, et al. Mesothelioma and Radical Surgery 2 (MARS 2): protocol for a multicentre randomised trial comparing (extended) pleurectomy decortication versus no (extended) pleurectomy decortication for patients with malignant pleural mesothelioma. BMJ Open 2020;10:e038892. [[doi: 10.1136/bmjopen-2020-038892]]. | ||
# Adhikary, SanjibDas; Pruett, Ashlee; Forero, Mauricio; Thiruvenkatarajan, Venkatesan (2018). "Erector spinae plane block as an alternative to epidural analgesia for post-operative analgesia following video-assisted thoracoscopic surgery: A case study and a literature review on the spread of local anaesthetic in the erector spinae plane". ''Indian Journal of Anaesthesia''. 62 (1): 75. [[Doi (identifier)|doi]]:10.4103/ija.IJA_693_17. [[ISSN (identifier)|ISSN]] 0019-5049. [[PMC (identifier)|PMC]] 5787896. [[PMID (identifier)|PMID]] 29416155. | |||
[[Category:Surgical procedures]] | [[Category:Surgical procedures]] |
Revision as of 09:50, 4 November 2021
Malignant pleural mesothelioma (MPM) is an aggressive disease, is often diagnosed at an advanced stage, and has a 5-year survival rate of only 5 to 10%.[1] The most important risk factor for its development is exposure to asbestos; the transformation of work practices worldwide has led to a modest decline in incidence. The three primary histologic types are epithelioid, sarcomatoid, and biphasic or mixed histology, with epithelioid resulting in more favorable outcomes than sarcomatoid or mixed histology.[2][3]
One of two operations is performed: extrapleural pneumonectomy (EPP) and pleurectomy/decortication (P/D). EPP is the radical en bloc resection of the lung, pleura, diaphragm, and pericardium. P/D is a lung-sparing but still radical procedure in which the diseased pleural envelope that encases and constricts the lung is dissected from the chest wall, mediastinum, diaphram, and pericardium, and then is stripped from the surface of the lung.[4][5][6]P/D is the more frequently used approach as of this writing as EPP has shown no survival advantage and patients experience improved quality of life when the lung remains intact.[7][8][9]
Currently a multi-center trial, MARS 2, is ongoing in the UK to test the hypothesis that P/D and chemotherapy is superior to chemotherapy alone with respect to overall survival for patients with pleural mesothelioma. The trial will also examine a range of secondary outcomes including adverse health events and cost-effectiveness. If the results of this trial are negative, there will be reason to question if radical surgery, as opposed to palliative procedures such as PleurX catheter insertion, should continue to have a role in the treatment of mesothelioma.[10]
This article will focus on the anesthetic management of radical pleurectomy/decortication, which is done via open thoracotomy with one-lung ventilation by double-lumen endotracheal tube. These procedures may last for eight hours or more, and typically involve substantial blood and fluid loss. Most centers send patients directly to ICU whether or not extubation is possible at the conclusion of surgery.
Preoperative management
Patients may present for P/D with substantial disease burden including decreased lung function on the affected side, pleural or pericardial effusion, anemia, poor nutritional status, and effects of neoadjuvant chemotherapy. If possible, prehabilitation in preparation for surgery should be considered to correct anemia, improve nutritional status, and improve functional capacity.
- Patient evaluation
System | Considerations |
---|---|
Cardiovascular | Consider stress testing, echocardiography; look for evidence of ventricular dysfunction, pulmonary hypertension, right heart strain from tumor involvement of pericardium |
Hematologic | Hypercoagulability due to underlying malignancy |
Respiratory | Pulmonary function testing; CT scan to evaluate extent of lung compression on the operative side, extent of pleural effusion |
Neurologic | Peripheral neuropathy due to chemotherapy; assess appropriateness for epidural analgesia |
Renal | Preexisting renal disease may worsen under stress of fluid shifts, blood loss, potential hypotension |
Operating room setup
The operating room setup will be for open thoracotomy with an operating room table that can be flexed.p- A checklist for equipment and supplies typically will include:
- Double-lumen endotracheal tube
- Fiberoptic bronchoscope
- Video laryngoscope
- Arterial line setup and transducer
- Consider flow parameter monitoring (e.g. FloTrac system, Edwards Lifesciences)
- IV fluid warming device
- Infusion pumps for vasoactive infusion
- Availability of cross-matched blood, albumin
- CPAP equipment with airflow and PEEP control
Patient preparation and premedication
Patients should fast per institutional guidelines. Premedication is at the choice of the anesthesiologist depending on the patient's age and other relevant factors.
Regional and neuraxial techniques
Thoracic epidural analgesia is highly recommended as it will benefit the patient's ability to breathe comfortably and resume mobility after the extensive thoracotomy required for radical mesothelioma resection.
The epidural catheter should be inserted at a high enough level that the patient will not have any lumbar motor block and can safely ambulate. Insertion prior to surgery offers the advantage of beginning epidural infusion before the patient emerges from anesthesia.
As there will be continuous blood and fluid loss throughout surgery, it may be preferred not to give any bolus dose or epidural infusion until close to the end of surgery to avoid the effects of sympathectomy. This decision must be weighed against the potential analgesic value of preemptive dosing.
If the patient has a contraindication to epidural catheter placement, other regional techniques may be considered: lumbar spinal opioid analgesia, erector spinae plane block [11], intercostal or paravertebral blocks.
Intraoperative management
Monitoring and access
Induction and airway management
Positioning
Maintenance and surgical considerations
Emergence
Postoperative management
Disposition
Pain management
Potential complications
Procedure variants
Variant 1 | Variant 2 | |
---|---|---|
Unique considerations | ||
Position | ||
Surgical time | ||
EBL | ||
Postoperative disposition | ||
Pain management | ||
Potential complications |
References
- Janes S, Alrefai D, Fennell D. Perspectives on the Treatment of Malignant Pleural Mesothelioma. N Engl J Med 2021; 385:1207-18. DOI: 10.1056/NEJMra1912719.
- Neragi-Miandoab, Siyamek, William G. Richards, and David J. Sugarbaker. “Morbidity, Mortality, Mean Survival, and the Impact of Histology on Survival after Pleurectomy in 64 Patients with Malignant Pleural Mesothelioma.” International Journal of Surgery (London, England) 6, no. 4 (August 2008): 293–97. https://doi.org/10.1016/j.ijsu.2008.04.004.
- Vigneswaran, Wickii T., Diana Y. Kircheva, Vijayalakshimi Ananthanarayanan, Sydeaka Watson, Qudsia Arif, Amy Durkin Celauro, Hedy L. Kindler, and Aliya N. Husain. “Amount of Epithelioid Differentiation Is a Predictor of Survival in Malignant Pleural Mesothelioma.” The Annals of Thoracic Surgery 103, no. 3 (March 1, 2017): 962–66. https://doi.org/10.1016/j.athoracsur.2016.08.063.
- Wolf, Andrea S., Jonathan Daniel, and David J. Sugarbaker. “Surgical Techniques for Multimodality Treatment of Malignant Pleural Mesothelioma: Extrapleural Pneumonectomy and Pleurectomy/Decortication.” Seminars in Thoracic and Cardiovascular Surgery, Multimodality Management of Malignant Pleural Mesothelioma, 21, no. 2 (June 1, 2009): 132–48. https://doi.org/10.1053/j.semtcvs.2009.07.007.
- Ng, Ju-Mei, and Philip M. Hartigan. “Anesthetic Management of Patients Undergoing Extrapleural Pneumonectomy for Mesothelioma.” Current Opinion in Anesthesiology 21, no. 1 (February 2008): 21. https://doi.org/10.1097/ACO.0b013e3282f2a9c3.
- Vlahu, Tedi, and Wicki T. Vigneswaran. “Pleurectomy and Decortication.” Annals of Translational Medicine 5, no. 11 (June 2017). https://doi.org/10.21037/atm.2017.04.03.
- Infante, Maurizio, Emanuela Morenghi, Edoardo Bottoni, Paolo Zucali, Daoud Rahal, Andrea Morlacchi, Anna Maria Ascolese, et al. “Comorbidity, Postoperative Morbidity and Survival in Patients Undergoing Radical Surgery for Malignant Pleural Mesothelioma.” European Journal of Cardio-Thoracic Surgery 50, no. 6 (December 2016): 1077–82. https://doi.org/10.1093/ejcts/ezw215.
- Sugarbaker, David J, and Andrea S Wolf. “Surgery for Malignant Pleural Mesothelioma.” Expert Review of Respiratory Medicine 4, no. 3 (June 2010): 363–72. https://doi.org/10.1586/ers.10.35.
- Neragi-Miandoab, Siyamek, Shoshana Weiner, and David J. Sugarbaker. “Incidence of Atrial Fibrillation after Extrapleural Pneumonectomy vs. Pleurectomy in Patients with Malignant Pleural Mesothelioma.” Interactive Cardiovascular and Thoracic Surgery 7, no. 6 (December 2008): 1039–42. https://doi.org/10.1510/icvts.2008.181099.
- Lim E, Darlison L, Edwards J On behalf of MARS 2 Trialists, et al. Mesothelioma and Radical Surgery 2 (MARS 2): protocol for a multicentre randomised trial comparing (extended) pleurectomy decortication versus no (extended) pleurectomy decortication for patients with malignant pleural mesothelioma. BMJ Open 2020;10:e038892. doi: 10.1136/bmjopen-2020-038892.
- Adhikary, SanjibDas; Pruett, Ashlee; Forero, Mauricio; Thiruvenkatarajan, Venkatesan (2018). "Erector spinae plane block as an alternative to epidural analgesia for post-operative analgesia following video-assisted thoracoscopic surgery: A case study and a literature review on the spread of local anaesthetic in the erector spinae plane". Indian Journal of Anaesthesia. 62 (1): 75. doi:10.4103/ija.IJA_693_17. ISSN 0019-5049. PMC 5787896. PMID 29416155.
- ↑ Janes, Sam M.; Alrifai, Doraid; Fennell, Dean A. (2021-09-23). Longo, Dan L. (ed.). "Perspectives on the Treatment of Malignant Pleural Mesothelioma". New England Journal of Medicine. 385 (13): 1207–1218. doi:10.1056/NEJMra1912719. ISSN 0028-4793.
- ↑ Neragi-Miandoab, Siyamek; Richards, William G.; Sugarbaker, David J. (2008-08-01). "Morbidity, mortality, mean survival, and the impact of histology on survival after pleurectomy in 64 patients with malignant pleural mesothelioma". International Journal of Surgery. 6 (4): 293–297. doi:10.1016/j.ijsu.2008.04.004. ISSN 1743-9191.
- ↑ Vigneswaran, Wickii T.; Kircheva, Diana Y.; Ananthanarayanan, Vijayalakshimi; Watson, Sydeaka; Arif, Qudsia; Celauro, Amy Durkin; Kindler, Hedy L.; Husain, Aliya N. (2017-03). "Amount of Epithelioid Differentiation Is a Predictor of Survival in Malignant Pleural Mesothelioma". The Annals of Thoracic Surgery. 103 (3): 962–966. doi:10.1016/j.athoracsur.2016.08.063. Check date values in:
|date=
(help) - ↑ Wolf, Andrea S.; Daniel, Jonathan; Sugarbaker, David J. (2009-06-01). "Surgical Techniques for Multimodality Treatment of Malignant Pleural Mesothelioma: Extrapleural Pneumonectomy and Pleurectomy/Decortication". Seminars in Thoracic and Cardiovascular Surgery. 21 (2): 132–148. doi:10.1053/j.semtcvs.2009.07.007. ISSN 1043-0679. PMID 19822285.
- ↑ Ng, Ju-Mei; Hartigan, Philip M. (2008-02). "Anesthetic management of patients undergoing extrapleural pneumonectomy for mesothelioma". Current Opinion in Anesthesiology. 21 (1): 21–27. doi:10.1097/ACO.0b013e3282f2a9c3. ISSN 0952-7907. Check date values in:
|date=
(help) - ↑ Vlahu, Tedi; Vigneswaran, Wicki T. (2017-07). "Pleurectomy and decortication". Annals of Translational Medicine. 5 (11): 246–246. doi:10.21037/atm.2017.04.03. PMC 5497109. PMID 28706914. Check date values in:
|date=
(help)CS1 maint: PMC format (link) - ↑ Infante, Maurizio; Morenghi, Emanuela; Bottoni, Edoardo; Zucali, Paolo; Rahal, Daoud; Morlacchi, Andrea; Ascolese, Anna Maria; De Rose, Fiorenza; Navarria, Pierina; Crepaldi, Alessandro; Testori, Alberto (2016-12). "Comorbidity, postoperative morbidity and survival in patients undergoing radical surgery for malignant pleural mesothelioma". European Journal of Cardio-Thoracic Surgery. 50 (6): 1077–1082. doi:10.1093/ejcts/ezw215. ISSN 1010-7940. Check date values in:
|date=
(help) - ↑ Sugarbaker, David J; Wolf, Andrea S (2010-06). "Surgery for malignant pleural mesothelioma". Expert Review of Respiratory Medicine. 4 (3): 363–372. doi:10.1586/ers.10.35. ISSN 1747-6348. Check date values in:
|date=
(help) - ↑ Neragi-Miandoab, S.; Weiner, S.; Sugarbaker, D. J. (2008-12-01). "Incidence of atrial fibrillation after extrapleural pneumonectomy vs. pleurectomy in patients with malignant pleural mesothelioma". Interactive CardioVascular and Thoracic Surgery. 7 (6): 1039–1042. doi:10.1510/icvts.2008.181099. ISSN 1569-9293.
- ↑ Lim, Eric; Darlison, Liz; Edwards, John; Elliott, Daisy; Fennell, D A; Popat, Sanjay; Rintoul, Robert C; Waller, David; Ali, Clinton; Bille, Andrea; Fuller, Liz (2020-08). "Mesothelioma and Radical Surgery 2 (MARS 2): protocol for a multicentre randomised trial comparing (extended) pleurectomy decortication versus no (extended) pleurectomy decortication for patients with malignant pleural mesothelioma". BMJ Open. 10 (9): e038892. doi:10.1136/bmjopen-2020-038892. ISSN 2044-6055. PMC 7467531. PMID 32873681. Check date values in:
|date=
(help)CS1 maint: PMC format (link) - ↑ Adhikary, SanjibDas; Pruett, Ashlee; Forero, Mauricio; Thiruvenkatarajan, Venkatesan (2018). "Erector spinae plane block as an alternative to epidural analgesia for post-operative analgesia following video-assisted thoracoscopic surgery: A case study and a literature review on the spread of local anaesthetic in the erector spinae plane". Indian Journal of Anaesthesia. 62 (1): 75. doi:10.4103/ija.IJA_693_17. ISSN 0019-5049. PMC 5787896. PMID 29416155.CS1 maint: PMC format (link)
Top contributors: Karen S Sibert, Nirav Kamdar and Chris Rishel